By Colin Kellaher


AbbVie Inc. on Thursday said a pair of Phase 3 induction studies of its psoriasis treatment Skyrizi met both primary endpoints in patients with Crohn's disease, a chronic inflammatory bowel disease.

The North Chicago, Ill., biopharmaceutical company said a significantly greater proportion of patients treated with either a 600-milligram or 1,200-milligram dose of Skyrizi showed statistically significant results for clinical remission and endoscopic response at week 12 compared to placebo.

The company also noted that the overall safety results in the studies were generally consistent with the known safety profile of the drug, with no new risks observed. AbbVie added that a maintenance study for Crohn's disease is continuing.

AbbVie earlier this week reported positive top-line results from two Phase 3 studies of Skyrizi in adults with active psoriatic arthritis.

The drug, which received U.S. and European approval in 2019 for adults with moderate to severe plaque psoriasis, is part of a collaboration between AbbVie and German pharmaceutical company Boehringer Ingelheim.


Write to Colin Kellaher at


(END) Dow Jones Newswires

January 07, 2021 09:41 ET (14:41 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.